161 related articles for article (PubMed ID: 37794102)
1. Mutations in the histone methyltransferase Ezh2 drive context-dependent leukemia in Xenopus tropicalis.
Tulkens D; Boelens M; Naert T; Carron M; Demuynck S; Dewaele S; Van Isterdael G; Creytens D; Pieters T; Goossens S; Van Vlierberghe P; Vleminckx K
Leukemia; 2023 Dec; 37(12):2404-2413. PubMed ID: 37794102
[TBL] [Abstract][Full Text] [Related]
2. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
4. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
O'Geen H; Bates SL; Carter SS; Nisson KA; Halmai J; Fink KD; Rhie SK; Farnham PJ; Segal DJ
Epigenetics Chromatin; 2019 May; 12(1):26. PubMed ID: 31053162
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.
Naert T; Tulkens D; Van Nieuwenhuysen T; Przybyl J; Demuynck S; van de Rijn M; Al-Jazrawe M; Alman BA; Coucke PJ; De Leeneer K; Vanhove C; Savvides SN; Creytens D; Vleminckx K
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34789568
[TBL] [Abstract][Full Text] [Related]
6. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
[TBL] [Abstract][Full Text] [Related]
7. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
Ernst T; Chase AJ; Score J; Hidalgo-Curtis CE; Bryant C; Jones AV; Waghorn K; Zoi K; Ross FM; Reiter A; Hochhaus A; Drexler HG; Duncombe A; Cervantes F; Oscier D; Boultwood J; Grand FH; Cross NC
Nat Genet; 2010 Aug; 42(8):722-6. PubMed ID: 20601953
[TBL] [Abstract][Full Text] [Related]
8. Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia.
Hamed NAM; El Ghandour A; Abo Elwafa RA; Rezk MR; Ghallab O
Asian Pac J Cancer Prev; 2023 Jan; 24(1):81-85. PubMed ID: 36708555
[TBL] [Abstract][Full Text] [Related]
9. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
Mechaal A; Menif S; Abbes S; Safra I
Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
[TBL] [Abstract][Full Text] [Related]
10. EZH2 in Myeloid Malignancies.
Rinke J; Chase A; Cross NCP; Hochhaus A; Ernst T
Cells; 2020 Jul; 9(7):. PubMed ID: 32650416
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
Sashida G; Iwama A
Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
[TBL] [Abstract][Full Text] [Related]
12. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
13. Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.
Booth CAG; Barkas N; Neo WH; Boukarabila H; Soilleux EJ; Giotopoulos G; Farnoud N; Giustacchini A; Ashley N; Carrelha J; Jamieson L; Atkinson D; Bouriez-Jones T; Prinjha RK; Milne TA; Teachey DT; Papaemmanuil E; Huntly BJP; Jacobsen SEW; Mead AJ
Cancer Cell; 2018 Feb; 33(2):274-291.e8. PubMed ID: 29438697
[TBL] [Abstract][Full Text] [Related]
14. Ezh2 Mutations Found in the Weaver Overgrowth Syndrome Cause a Partial Loss of H3K27 Histone Methyltransferase Activity.
Lui JC; Barnes KM; Dong L; Yue S; Graber E; Rapaport R; Dauber A; Nilsson O; Baron J
J Clin Endocrinol Metab; 2018 Apr; 103(4):1470-1478. PubMed ID: 29244146
[TBL] [Abstract][Full Text] [Related]
15. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
16. Cancer Models in Xenopus tropicalis by CRISPR/Cas9 Mediated Knockout of Tumor Suppressors.
Naert T; Vleminckx K
Methods Mol Biol; 2018; 1865():147-161. PubMed ID: 30151765
[TBL] [Abstract][Full Text] [Related]
17. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract][Full Text] [Related]
18. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells
Al-Ghabkari A; Narendran A
Cancer Biol Ther; 2021 Apr; 22(4):333-344. PubMed ID: 33978549
[TBL] [Abstract][Full Text] [Related]
19. The NSD1 and EZH2 overgrowth genes, similarities and differences.
Tatton-Brown K; Rahman N
Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):86-91. PubMed ID: 23592277
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
